Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer's disease

Paul Armstrong,Hüseyin Güngör,Pariya Anongjanya,Clare Tweedy,Edward Parkin,Jamie Johnston,Ian M. Carr,Neil Dawson,Steven J. Clapcote

DOI: https://doi.org/10.1038/s41386-024-01852-z

2024-03-24

Neuropsychopharmacology

Abstract:Meta-analysis of genome-wide association study data has implicated PDE4B in the pathogenesis of Alzheimer's disease (AD), the leading cause of senile dementia. PDE4B encodes one of four subtypes of cyclic adenosine monophosphate (cAMP)-specific phosphodiesterase-4 (PDE4A–D). To interrogate the involvement of PDE4B in the manifestation of AD-related phenotypes, the effects of a hypomorphic mutation ( Pde4b Y358C ) that decreases PDE4B's cAMP hydrolytic activity were evaluated in the App NL-G-F knock-in mouse model of AD using the Barnes maze test of spatial memory, 14 C-2-deoxyglucose autoradiography, thioflavin-S staining of β-amyloid (Aβ) plaques, and inflammatory marker assay and transcriptomic analysis (RNA sequencing) of cerebral cortical tissue. At 12 months of age, App NL-G-F mice exhibited spatial memory and brain metabolism deficits, which were prevented by the hypomorphic PDE4B in App NL-G-F / Pde4b Y358C mice, without a decrease in Aβ plaque burden. RNA sequencing revealed that, among the 531 transcripts differentially expressed in App NL-G-F versus wild-type mice, only 13 transcripts from four genes – Ide , Btaf1 , Padi2, and C1qb – were differentially expressed in App NL-G-F / Pde4b Y358C versus App NL-G-F mice, identifying their potential involvement in the protective effect of hypomorphic PDE4B. Our data demonstrate that spatial memory and cerebral glucose metabolism deficits exhibited by 12-month-old App NL-G-F mice are prevented by targeted inhibition of PDE4B. To our knowledge, this is the first demonstration of a protective effect of PDE4B subtype-specific inhibition in a preclinical model of AD. It thus identifies PDE4B as a key regulator of disease manifestation in the App NL-G-F model and a promising therapeutic target for AD.

pharmacology & pharmacy,neurosciences,psychiatry

What problem does this paper attempt to address?

This paper aims to explore the protective effect of PDE4B subtype - specific inhibition in a mouse model of Alzheimer's disease (AD). Specifically, the study investigated the role of PDE4B in AD - related phenotypes by evaluating the effect of a hypomorphic mutation (Pde4bY358C) that causes a decrease in PDE4B cAMP hydrolytic activity in the AppNL - G - F knock - in mouse model. The study used methods such as the Barnes maze test for spatial memory, 14C - 2 - deoxyglucose autoradiography to assess brain metabolism, thioflavin S staining to detect β - amyloid (Aβ) plaques, determination of inflammatory markers, and transcriptome analysis (RNA sequencing).

The study found that 12 - month - old AppNL - G - F mice exhibited spatial memory impairment and brain metabolism defects, and these defects were prevented in AppNL - G - F/Pde4bY358C mice carrying the Pde4bY358C mutation without reducing the Aβ plaque burden. RNA sequencing results showed that among the 531 transcripts differentially expressed between AppNL - G - F and wild - type mice, only 13 transcripts from four genes (Ide, Btaf1, Padi2, and C1qb) were differentially expressed between AppNL - G - F/Pde4bY358C and AppNL - G - F mice, suggesting that they may be involved in the protective effect of the PDE4B hypomorphic phenotype.

In conclusion, this study is the first to demonstrate that PDE4B subtype - specific inhibition has a protective effect in a preclinical model of AD, identifies PDE4B as a key regulator of disease manifestation in the AppNL - G - F model, and proposes PDE4B as a potential target for AD treatment.